$BLUE
bluebird bio, Inc.

2016 Q1 Form 10-Q Financial Statement

#000156459016017668 Filed on May 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q1 2015 Q1
Revenue $1.499M $6.344M
YoY Change -76.37% 0.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.00M $7.300M
YoY Change 119.18% 32.73%
% of Gross Profit
Research & Development $41.91M $23.72M
YoY Change 76.7% 106.92%
% of Gross Profit
Depreciation & Amortization $2.280M $1.710M
YoY Change 33.33% 256.25%
% of Gross Profit
Operating Expenses $58.88M $31.27M
YoY Change 88.29% 83.91%
Operating Profit -$57.38M -$24.93M
YoY Change 130.2% 133.65%
Interest Expense -$1.000M -$200.0K
YoY Change 400.0%
% of Operating Profit
Other Income/Expense, Net $961.0K $139.0K
YoY Change 591.37% 135.59%
Pretax Income -$56.42M -$24.79M
YoY Change 127.62% 133.84%
Income Tax -$145.0K
% Of Pretax Income
Net Earnings -$56.27M -$24.79M
YoY Change 127.03% 133.64%
Net Earnings / Revenue -3754.1% -390.72%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.526M -$760.7K
COMMON SHARES
Basic Shares Outstanding 36.93M 32.57M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $553.1M $334.9M
YoY Change 65.15% 73.97%
Cash & Equivalents $192.6M $133.2M
Short-Term Investments $360.5M $201.7M
Other Short-Term Assets $7.900M $5.900M
YoY Change 33.9% 73.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $561.0M $340.8M
YoY Change 64.6% 73.97%
LONG-TERM ASSETS
Property, Plant & Equipment $96.60M $16.85M
YoY Change 473.29% 40.6%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $23.52M $27.28M
YoY Change -13.79%
Long-Term Investments $273.8M $134.4M
YoY Change 103.72%
Other Assets $10.69M $1.294M
YoY Change 725.81% -19.13%
Total Long-Term Assets $417.7M $193.0M
YoY Change 116.45% 1320.01%
TOTAL ASSETS
Total Short-Term Assets $561.0M $340.8M
Total Long-Term Assets $417.7M $193.0M
Total Assets $978.7M $533.8M
YoY Change 83.34% 154.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.136M $2.551M
YoY Change 22.93% -1.92%
Accrued Expenses $23.30M $15.10M
YoY Change 54.3% 190.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $38.97M $42.01M
YoY Change -7.25% 27.13%
LONG-TERM LIABILITIES
Long-Term Debt $74.40M $0.00
YoY Change
Other Long-Term Liabilities $58.80M $265.0K
YoY Change 22088.68% -31.17%
Total Long-Term Liabilities $133.2M $265.0K
YoY Change 50164.15% -31.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $38.97M $42.01M
Total Long-Term Liabilities $133.2M $265.0K
Total Liabilities $172.2M $59.32M
YoY Change 190.3% -9.22%
SHAREHOLDERS EQUITY
Retained Earnings -$172.2M
YoY Change 57.54%
Common Stock $327.0K
YoY Change 34.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $806.5M $474.5M
YoY Change
Total Liabilities & Shareholders Equity $978.7M $533.8M
YoY Change 83.34% 154.79%

Cashflow Statement

Concept 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$56.27M -$24.79M
YoY Change 127.03% 133.64%
Depreciation, Depletion And Amortization $2.280M $1.710M
YoY Change 33.33% 256.25%
Cash From Operating Activities -$36.77M -$24.16M
YoY Change 52.19% 102.51%
INVESTING ACTIVITIES
Capital Expenditures $3.894M $1.156M
YoY Change 236.85% -54.07%
Acquisitions
YoY Change
Other Investing Activities $68.34M -$191.8M
YoY Change -135.63%
Cash From Investing Activities $64.45M -$193.0M
YoY Change -133.4% 7557.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $639.0K $2.464M
YoY Change -74.07% 267.21%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 640.0K 2.460M
YoY Change -73.98% 267.16%
NET CHANGE
Cash From Operating Activities -36.77M -24.16M
Cash From Investing Activities 64.45M -193.0M
Cash From Financing Activities 640.0K 2.460M
Net Change In Cash 28.32M -214.7M
YoY Change -113.19% 1457.91%
FREE CASH FLOW
Cash From Operating Activities -$36.77M -$24.16M
Capital Expenditures $3.894M $1.156M
Free Cash Flow -$40.66M -$25.32M
YoY Change 60.63% 75.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
23516000
CY2016Q1 us-gaap Goodwill
Goodwill
13128000
CY2016Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10686000
CY2016Q1 us-gaap Assets
Assets
978704000
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3136000
CY2016Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
29623000
CY2016Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6209000
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
38968000
CY2016Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8498000
CY2016Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
5248000
CY2016Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
44861000
CY2016Q1 us-gaap Revenues
Revenues
1499000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41911000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23719000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15955000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7336000
CY2016Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1013000
CY2015Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
215000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
58879000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
31270000
CY2016Q1 blue Construction Financing Obligation
ConstructionFinancingObligation
74414000
CY2015Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31200000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
64446000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133174000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57380000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
961000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
139000
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56419000
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24787000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-145000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-56274000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-24787000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36920000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1319000
CY2015Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-52000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54955000
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24839000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
700000
CY2016Q1 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
1013000
CY2015Q1 blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
215000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2283000
CY2015Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1710000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10143000
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5432000
CY2016Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
868000
CY2015Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
130000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2271000
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2195000
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-331000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
211000
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
88000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
9222000
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6344000
CY2016Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
234000
CY2015Q1 blue Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-270000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36766000
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-24159000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3894000
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1156000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
28175000
CY2015Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223020000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
96515000
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-192976000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
639000
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2464000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
639000
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2464000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28319000
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-214671000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347845000
CY2016Q1 blue Construction Financing Obligation Non Cash
ConstructionFinancingObligationNonCash
12513000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1086000
CY2015Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1125000
CY2015Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P5Y
CY2013Q2 blue Landlord Contribution For Leasehold Improvements
LandlordContributionForLeaseholdImprovements
7800000
CY2016Q1 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
4431000
CY2016Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
104796000
CY2016Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic and rare diseases and in the field of T cell-based immunotherapy. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div>
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
89435000
CY2016Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8158000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6821000
CY2014Q4 us-gaap Operating Leases Rent Expense Contingent Rentals
OperatingLeasesRentExpenseContingentRentals
300000
CY2016Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.33%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Estimates are used in the following areas, among others: fair value estimates used to assess potential impairment of long-lived assets, construction financing lease obligations, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes. Actual results could materially differ from those estimates.</p></div>
CY2016Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4394000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5935000
CY2016Q1 blue Accrued Goods And Services
AccruedGoodsAndServices
18012000
CY2015Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
16153000
CY2016Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
914000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1014000
CY2016Q1 blue Date Of Incorporation
DateOfIncorporation
1992-04-16
CY2016Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
634543000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
703785000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
104000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2016Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
370000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2313000
CY2016Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
634277000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
701494000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
865763000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
8665000
CY2016Q1 us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Three months or less
CY2016Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
411700000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
638100000
CY2016Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
43300000
CY2016Q1 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2016Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
994000
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
964000
CY2015Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
3584000
CY2016Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
878000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
495000
CY2013Q2 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P9Y
CY2013Q2 blue Area Of Leased Space
AreaOfLeasedSpace
43600
CY2013Q2 blue Lease Amendment Effective Month And Year
LeaseAmendmentEffectiveMonthAndYear
2014-06
CY2013Q2 blue Additional Lease Space Agreement
AdditionalLeaseSpaceAgreement
9900
CY2013Q2 us-gaap Operating Leases Rent Expense Minimum Rentals
OperatingLeasesRentExpenseMinimumRentals
200000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1300000
CY2013Q2 blue Letter Of Credit Related To New Lease Agreement
LetterOfCreditRelatedToNewLeaseAgreement
1300000
CY2013Q2 blue Lease Starting Date
LeaseStartingDate
2013-06-03
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1500000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10143000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3532000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
713000
CY2016Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
108000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4104000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1538000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4017000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.74
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
50.93
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
14.34
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.54
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.94
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.29
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
50.48
CY2016Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
500000
CY2016Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
600000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4434000
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4525000

Files In Submission

Name View Source Status
0001564590-16-017668-index-headers.html Edgar Link pending
0001564590-16-017668-index.html Edgar Link pending
0001564590-16-017668.txt Edgar Link pending
0001564590-16-017668-xbrl.zip Edgar Link pending
blue-10q_20160331.htm Edgar Link pending
blue-20160331.xml Edgar Link completed
blue-20160331.xsd Edgar Link pending
blue-20160331_cal.xml Edgar Link unprocessable
blue-20160331_def.xml Edgar Link unprocessable
blue-20160331_lab.xml Edgar Link unprocessable
blue-20160331_pre.xml Edgar Link unprocessable
blue-ex1015_496.htm Edgar Link pending
blue-ex1016_497.htm Edgar Link pending
blue-ex1017_498.htm Edgar Link pending
blue-ex1018_499.htm Edgar Link pending
blue-ex1025_500.htm Edgar Link pending
blue-ex1027_501.htm Edgar Link pending
blue-ex311_8.htm Edgar Link pending
blue-ex312_6.htm Edgar Link pending
blue-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gui1pn5l3a5h000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending